SCHEMBL2235510

SCHEMBL2235510

CC(C)(C)OC(=O)NCCCC(Cc1ncn2c1CCc1cc(OC3CCCCC3)ccc1-2)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
ACE P12821 1/20 0.35
CPB2 Q96IY4 3/20 0.34
CA12 O43570 4/20 0.33
CA1 P00915 4/20 0.33
CA2 P00918 4/20 0.33
CA9 Q16790 4/20 0.33
BCHE P06276 2/20 0.33
ACHE P22303 1/20 0.33
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
PDK1 Q15118 1/20 0.32
PDK2 Q15119 1/20 0.32
PDK3 Q15120 1/20 0.32
PDK4 Q16654 1/20 0.32
EGLN2 Q96KS0 1/20 0.32
EGLN1 Q9GZT9 1/20 0.32
DYRK1A Q13627 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235898 0.88 MEN1 (0.40) MEN1GAAKMT2AACECPB2
SCHEMBL2235434 0.88 MEN1 (0.42) MEN1GAAKMT2AACECPB2
SCHEMBL2234527 0.86 MEN1 (0.38) MEN1GAAKMT2AACECPB2
SCHEMBL2235504 0.86 PPARG (0.39) MEN1GAAKMT2AACECPB2
SCHEMBL2234528 0.86 PPARG (0.39) MEN1GAAKMT2AACECPB2
SCHEMBL2233578 0.85 CPB2 (0.47) CPB2
SCHEMBL2235169 0.85 MEN1 (0.44) MEN1GAAKMT2AACECYP11B1
SCHEMBL2237252 0.85 MEN1 (0.44) MEN1GAAKMT2AACECYP11B1
SCHEMBL2234628 0.85 MEN1 (0.43) MEN1GAAKMT2AACECYP11B1
SCHEMBL2237078 0.85 MEN1 (0.43) MEN1GAAKMT2AACECYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-01 US disclosed
EP-2361910-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY Taisho Pharmaceutical Co., Ltd. (JP) 2011-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAF1, TAF5, TAF11 MEN1 4119/4885GAA 1535/4885KMT2A 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.